Form 4: Rocket Pharmaceuticals Director, Keith Woods, Acquires Stock Options

Director Keith Woods acquired options to purchase 23,944 shares of Rocket Pharmaceuticals stock on June 13, 2024.

Summary

• Keith Woods, a director of Rocket Pharmaceuticals, acquired stock options on June 13, 2024.
• The options grant the right to purchase 23,944 shares of the company's common stock at a price of $22.86 per share.
• These options will fully vest and become exercisable on June 13, 2025.
• Following the transaction, Woods directly owns 23,944 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director generally indicates confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options to their leadership teams as incentives for driving long-term shareholder value.
• The vesting schedule of one year is fairly standard.

Stakeholder Impact

• The acquisition of stock options by a director can have a slightly positive impact on shareholder sentiment.

Key Dates